Telomir Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Mar 17, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 17, 2026
TELO$0.57-17.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2025 and 2024
BALANCE SHEETS
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| Current assets: | ||
| Cash | $7,286,670 | $1,266,131 |
| Prepaid expenses | 54,691 | 57,874 |
| Total current assets | 7,341,361 | 1,324,005 |
| Total assets | $7,341,361 | $1,324,005 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Trade accounts payable and accrued liabilities | $536,769 | $587,536 |
| Due to officer | 155,518 | - |
| Accrued compensation - officer | 417,470 | - |
| Due to related parties | 318,234 | 93,432 |
| Total current liabilities | 1,427,991 | 680,968 |
| Total liabilities | 1,427,991 | 680,968 |
| Stockholders’ Equity | ||
| Preferred Stock, no par value, 100,000,000 shares authorized and none issued or outstanding. | - | - |
| Common Stock, no par value; 300,000,000 shares authorized, 34,380,971 and 29,762,671 shares issued and outstanding at December 31, 2025 and 2024, respectively. | - | - |
| Additional paid-in capital | 46,923,433 | 31,239,895 |
| Accumulated deficit | (41,010,063) | (30,596,858) |
| Total stockholders’ equity | 5,913,370 | 643,037 |
| Total liabilities and stockholders’ equity | $7,341,361 | $1,324,005 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.